F2RL1 Knockout OE33 Cell Line

The choice depends on whether you are studying F2RL1 (PAR2, protease-activated receptor 2)'s role as a tryptase/trypsin/elastase-activated GPCR or modeling its functions in inflammation, itch, and gastrointestinal disease. The Knockout line is the standard tool for asking whether PAR2 is required for these processes — F2RL1/PAR2 is one of four PAR family GPCRs (PAR1/F2R, PAR2/F2RL1, PAR3/F2RL2, PAR4/F2RL3) activated by proteolytic cleavage of the extracellular N-terminus, exposing a tethered ligand; PAR2 is activated by mast cell tryptase, trypsin, neutrophil elastase, and other serine proteases, with established roles in inflammation, pain, itch, and GI biology. Overexpression is useful for studying PAR2 in heterologous expression contexts. For gastrointestinal/esophageal research, the EDITGENE F2RL1 Knockout in OE33 is highly relevant — OE33 is an esophageal adenocarcinoma cell line, and PAR2 has been characterized in Barrett's esophagus and esophageal adenocarcinoma biology with implications for GERD-related disease. Rescue with wild-type or cleavage-resistant (Arg36Ala — the tryptase/trypsin cleavage site) PAR2 enables structure-function studies. The knockout is a critical specificity control for PAR2 antagonists (PZ-235, GB88) in asthma, IBD, and itch drug development.

Primary applications: • PAR2 activation: cellular calcium mobilization, ERK activation following trypsin, tryptase, or PAR2-AP (SLIGRL-NH2 activating peptide) stimulation in PAR2-null cells. • Esophageal adenocarcinoma biology: in OE33 context, characterization of PAR2's role in Barrett's esophagus and adenocarcinoma progression. • PAR2 antagonist specificity: critical genetic control for PZ-235, GB88, and other PAR2-targeting compounds in asthma, IBD, and chronic itch drug development. • Biased agonism studies: G-protein versus β-arrestin biased PAR2 ligands. EDITGENE recommends this OE33-based model for researchers investigating esophageal adenocarcinoma PAR2 biology and PAR2-targeted inflammation therapeutic development.

Yes. PAR2 rescue experiments require attention to protease cleavage activation: • Construct design: use a codon-modified F2RL1 sequence with a small intracellular C-terminal tag (FLAG, HA). PAR2 is a seven-transmembrane GPCR — preserve N-terminal extracellular tail with cleavage sites. • Cleavage-site-mutant rescue: R36A mutation in the tryptase/trypsin cleavage site (S37LIGRL... tethered ligand) abolishes protease activation; this generates a PAR2 that responds only to exogenous activating peptides (PAR2-AP), enabling separation of biased activation modes. • Surface localization validation: confirm plasma membrane localization before functional assays. • Functional readout: rescue should restore protease-induced PAR2 activation measured by Ca²⁺ mobilization and ERK phosphorylation. OE33-specific considerations: • OE33 is a human esophageal adenocarcinoma cell line derived from Barrett's esophagus-associated adenocarcinoma — a relevant model for esophageal adenocarcinoma biology, which has a rising incidence in Western countries. • Lentiviral transduction is supported with moderate efficiency. • OE33's esophageal adenocarcinoma origin makes it relevant for studying gastrointestinal Barrett's progression and adenocarcinoma biology.